| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 07/18/2006 | US7078017 Delivery of sedative-hypnotics through an inhalation route |
| 07/18/2006 | CA2313629C Method for transferring one or more active ingredients between different phase carriers |
| 07/18/2006 | CA2132007C Method for reducing intraocular pressure in the mammalian eye by administration of muscarinic antagonists |
| 07/13/2006 | WO2006074296A1 Surfactant treatment regimen for treating or preventing bronchopulmonary dysplasia |
| 07/13/2006 | WO2006074182A2 Growth factor therapy mobilization of stem cells into the peripheral blood |
| 07/13/2006 | WO2006074094A2 Method for producing probiotically derived compounds |
| 07/13/2006 | WO2006073573A1 Posterior stabilization system |
| 07/13/2006 | WO2006073467A1 Anti-itch cloth for women |
| 07/13/2006 | WO2006073197A1 1-thio-d-glucitol derivatives |
| 07/13/2006 | WO2006073181A1 Cell activator, cell death inhibitor and cell death promoter |
| 07/13/2006 | WO2006073052A1 Novel angiogensis inhibitor |
| 07/13/2006 | WO2006047522A8 Hypoestoxides, derivatives, agonists and crude extracts thereof for use in topical compositions |
| 07/13/2006 | WO2005123109A3 Pegylation of vasoactive intestinal peptide (vip)/pituitary adenylate cyclase activating peptide (pacap) receptor 2 (vpac2) agonists and methods of use |
| 07/13/2006 | WO2005120475A3 Pharmaceutical composition for the treatment of bacterial infections and sepsis |
| 07/13/2006 | WO2005110478A3 Combination therapy for treating fibrotic disorders |
| 07/13/2006 | WO2005110413A3 Medicaments containing n-sulfamoyl-n'-arylpiperazines for the prophylaxis or treatment of obesity and related conditions |
| 07/13/2006 | WO2005084710A3 Nanocell drug delivery system |
| 07/13/2006 | WO2005074990A3 Methods of preventing and treating sars using low ph respiratory tract compositions |
| 07/13/2006 | WO2003095621A3 Apoptotic ebv-transformed lymphocytes, a therapeutic agent for post-transplant lymphoproliferactive disorder |
| 07/13/2006 | US20060155111 Novel genes and their use in the modulation of obesity, diabetes and energy imbalance |
| 07/13/2006 | US20060154976 Reducing the incidence of fibrosis by the co-administration of effective amounts of telmisartan and ramipril; strokes; cardiovascular disorders; organoprotective, tissue-protective, and vasculoprotective effects of combined treatment |
| 07/13/2006 | US20060154954 Combinations and use of selected pharmaceutically active compounds |
| 07/13/2006 | US20060154938 Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders |
| 07/13/2006 | US20060154936 Use of n-'5-'4-(4-methylpiperaziomethyl)-benzoylamido!-2-methylphenyl!-4-(3-pyridyl)2-pyridine-amine for the treatment of pulmonary hypertension |
| 07/13/2006 | US20060154934 Combinations comprising antimuscarinic agents and PDE4 inhibitors |
| 07/13/2006 | US20060154932 Pharmaceutical compositions and method of treating parkinson's disease |
| 07/13/2006 | US20060154892 Procedure to block the replication of reverse transcriptase dependent viruses by the use of inhibitors of deoxynucleotides synthesis |
| 07/13/2006 | US20060154876 Serum cholesterol lowering agent or preventive or therapeutic agent for atherosclerosis |
| 07/13/2006 | US20060154874 Treatment of symptoms associated with bacterial vaginosis |
| 07/13/2006 | US20060154868 Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis |
| 07/13/2006 | US20060154339 Novel clock gene BMAL2 |
| 07/13/2006 | US20060154295 Nucleotide sequence which encodes a flavin monooxygenase, the corresponding protein and their uses in the spheres of diagnosis and therapy |
| 07/13/2006 | US20060154294 Interleukin-18 binding proteins, their preparation and use |
| 07/13/2006 | US20060154252 Methods and composition for identifying therapeutic agents of atherosclerotic plaque lesions |
| 07/13/2006 | US20060153931 Prevention of flap necrosis in plastic surgery |
| 07/13/2006 | US20060153930 Drug-containing sustained release microparticle, process for producing the same and preparation containing the microparticle |
| 07/13/2006 | US20060153906 Pharmaceutical product for endonasal administration for treating central nervous system disease and disorders |
| 07/13/2006 | US20060153859 Ganglioside-KLH conjugate vaccine with QS-21 |
| 07/13/2006 | US20060153848 Synergistic composition and methods for treating neoplastic or cancerous growths and for restoring or boosting hematopoiesis |
| 07/13/2006 | US20060153845 Method for correcting immune respones and medical agent |
| 07/13/2006 | US20060153842 Immunosuppressive combination and its use in the treatment or prophylaxis or insulin-producing cell graft rejection |
| 07/13/2006 | US20060153841 Nucleotide sequence which hybridizes to the complement of the specific nucleic acid molecule over its full length under conditions of incubation and encodes a polypeptide which costimulates T cell proliferation in vitro |
| 07/13/2006 | US20060153836 Using monoclonal antibody specific for kidney injury-molecule-1 (KIM-1) to diagnose, prevent and treat cell proliferative and kidney disorders; immunotherapeutics |
| 07/13/2006 | US20060153832 Immunomodulating polymers |
| 07/13/2006 | US20060153794 Hair tonics and method of screening the same |
| 07/13/2006 | US20060153779 Rapidly producing peak plasma concentration; condensation aerosol containing ephedrine and/or fenfluramine; vaporization without degradation |
| 07/13/2006 | DE102004063754A1 Use of a calcitonin gene related peptide antagonist and a serotonin reuptake inhibitor to treat headaches, migraine and cluster headaches |
| 07/13/2006 | DE102004063753A1 Verwendung ausgewählter CGRP-Antagonisten in Kombination mit anderen Arzneistoffen gegen Migräne für die Behandlung von Migräne Use of selected CGRP antagonists in combination with other drugs for migraine for the treatment of migraine |
| 07/13/2006 | CA2830842A1 Method for producing probiotically derived compounds |
| 07/13/2006 | CA2594187A1 Method for producing probiotically derived compounds |
| 07/13/2006 | CA2593758A1 Surfactant treatment regimen for treating or preventing bronchopulmonary dysplasia |
| 07/13/2006 | CA2591995A1 Anti-itch cloth for women |
| 07/12/2006 | EP1679371A1 Method of evaluating cancerization degree |
| 07/12/2006 | EP1679370A1 Method of evaluating cancerization degree |
| 07/12/2006 | EP1679067A1 Concurrent drugs |
| 07/12/2006 | EP1677846A2 Bioactive hydrogel compositions for regenerating connective tissue |
| 07/12/2006 | EP1677831A1 Plasmid encoding fibroblast growth factor for the treatment of hypercholesterolemia or diabetes associated angiogenic defects |
| 07/12/2006 | EP1677827A2 Combinations for hcv treatment |
| 07/12/2006 | EP1677806A1 Methods for treating acute and overuse sprain and strain using hyaluronic acid |
| 07/12/2006 | EP1677804A1 Silyl phenols for promoting vascular health |
| 07/12/2006 | EP1677803A2 Method of inhibiting the expression of a multi-drug resistance genes and inhibiting the production of proteins resulting from the expression of such genes thereby enhancing the effectiveness of chemotherapeutic agents to treat cancers |
| 07/12/2006 | EP1677792A1 Solid preparation comprising an insulin sensitizer, an insulin secretagogue and a polyoxyethylene sorbitan fatty acid ester |
| 07/12/2006 | EP1677787A1 Combinations of potassium channel openers and sodium channel inhibitors or active substances influencing sodium channels in order to treat painful conditions |
| 07/12/2006 | EP1677781A1 Salts of pharmacologically active compounds |
| 07/12/2006 | EP1677772A1 Oral antidepressant formulation comprising acetylsalicylic acid to accelerate onset of action |
| 07/12/2006 | EP1677771A2 Transdermal analgesic systems having reduced abuse potential |
| 07/12/2006 | EP1677760A2 Controlled release analgesic suspensions |
| 07/12/2006 | EP1677732A2 Disinfecting teat care compositions |
| 07/12/2006 | EP1677701A2 Method and material for enhance tissue-biomaterial integration |
| 07/12/2006 | EP1509239A4 Composition and method for reducing post-prandial blood glucose |
| 07/12/2006 | EP1289557B1 Cancer treatment composition containing an anti-neoplastic agent and a pde4 inhibitor |
| 07/12/2006 | EP1263435B1 Pharmaceutical composition for treatment and prevention of liver fibrosis and cirrhosis |
| 07/12/2006 | EP1237559B1 Pharmaceutical combinations comprising a p2t receptor antagonist and melagatran |
| 07/12/2006 | EP1124950B1 Morpholino based p53 antisense oligonucleotide, and uses thereof |
| 07/12/2006 | EP1121439B1 Methods and compositions for inhibiting neoplastic cell growth |
| 07/12/2006 | EP1121157B1 A novel component in the hedgehog signalling pathway |
| 07/12/2006 | EP1023074B1 Methods for treating psychosis associated with glucocorticoid related dysfunction |
| 07/12/2006 | EP1015002B1 Aluminium free mixed metal compounds as phosphate binders |
| 07/12/2006 | EP0971743B1 Stabilized medicaments containing cysteinyl derivatives |
| 07/12/2006 | EP0876396B1 MIMOTOPES AND ANTI-MIMOTOPES OF HUMAN PLATELET GLYCOPROTEIN Ib/IX |
| 07/12/2006 | EP0788359B1 Combination of dextromethorphan with quinidine or quinine sulfate for treating a variety of intractable disorders |
| 07/12/2006 | CN1802178A Solid formulation |
| 07/12/2006 | CN1802177A Inhibitors of phosphodiesterases in infertility |
| 07/12/2006 | CN1802162A Compositions for prevention and treatment of cold and influenza-like symptoms comprising chelated zinc |
| 07/12/2006 | CN1802152A Improved treatment of cancer with glutamine |
| 07/12/2006 | CN1802102A Enteral composition for the prevention and/or treatment of sepsis |
| 07/12/2006 | CN1799629A Self-assembled luminous current-conducting nano medicine crystal and ultra-thin film and preparation method thereof |
| 07/12/2006 | CN1263757C Compounds specific to adenosine A1, A2, and A3 receptor and uses thereof |
| 07/12/2006 | CN1263739C Carboxypeptidase U suppressed compound and its preparation method, pharmaceutical composition containing the compound and its uses |
| 07/12/2006 | CN1263730C Esters of L-carnitine or alkanoyl L-carnitines used as cation lipid for intracellular release pharmacological activity compound |
| 07/12/2006 | CN1263512C Concomitant drugs for treating glaucoma |
| 07/12/2006 | CN1263446C Self emulsifying lipid matrix (SELM) |
| 07/12/2006 | CA2489780A1 Methods for preventing or treating a condition or a disease associated with angiogenesis |
| 07/11/2006 | US7074938 Method for the synthesis of soritin compounds |
| 07/11/2006 | US7074909 Prevent, therapy of disease; isolated nucleic acid which codes antibody; binding to human antigen |
| 07/11/2006 | US7074901 Nucleotide sequences coding polypeptides for use in the tumor/cancer therapy |
| 07/11/2006 | US7074896 Gene expression of nucleic acid in prokaryotic cells; homogeneity, purity; immobilization; separation of antibodies by chromatography |
| 07/11/2006 | US7074825 Using hydroxy-3-methylglutaryl/3-/ coenzyme a inhibitors; synergistic mixtures ; cell antigrowth agents |
| 07/11/2006 | US7074789 Kinase inhibitors |
| 07/11/2006 | US7074779 Osteoporosis; menopause; breast cancer; endometriosis; contraceptiives |